Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...

Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with ...

This can be explained by the first generation weight loss product that Novo Nordisk had launched, Saxenda (liraglutide), which had been approved by the FDA to treat obesity in 2014. The product ...

Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new ... obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2 programme for the drug ...

New Precision Medicine Approach Helps Detect Subgroups of People With Obesity at High Risk of Diabetes ... the age of 50 take cholesterol-lowering drugs to prevent heart disease and strokes ...